|
CN110072525A
|
|
The solid dispersion form of rifaximin
|
|
US2017087134A1
|
|
Formulations of rifaximin and uses thereof
|
|
AU2015203018A1
|
|
New forms of rifaximin and uses thereof
|
|
HK1203373A1
|
|
Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
|
|
WO2014003834A1
|
|
Method of stably treating incontinence using a bulking agent
|
|
MX2014007312A
|
|
Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone.
|
|
AU2012332211A1
|
|
Methods for treating irritable bowel syndrome (IBS) and infections
|
|
AU2012214239A1
|
|
Forms of Rifaximin and uses thereof
|
|
NZ605232A
|
|
Formulations of rifaximin and uses thereof
|
|
AU2011261283A1
|
|
New forms of rifaximin and uses thereof
|
|
MY158656A
|
|
New form of rifaximin and use thereof
|
|
WO2011137103A1
|
|
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
|
|
WO2011103246A1
|
|
Methods for treating infection
|
|
GEP201706745B
|
|
Forms of rifaximin and usage thereof
|
|
US2011065740A1
|
|
Methods of treating travelers diarrhea and hepatic encephalopathy
|
|
WO2011032085A1
|
|
Methods for treating irritable bowel syndrome (ibs)
|
|
TN2010000377A1
|
|
Forms of rifaximin and uses thereof
|
|
KR20120030542A
|
|
Modulation of systemic exposure to rifaximin
|
|
MX2011012829A
|
|
Methods of treating hepatic encephalopathy.
|
|
CA2763894A1
|
|
Use of rifaximin to maintain remission of hepatic encephalopathy
|
